These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 18215698

  • 1. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
    Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ.
    Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
    [Abstract] [Full Text] [Related]

  • 2. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 3. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 4. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.
    Clin J Am Soc Nephrol; 2009 Mar 29; 4(3):542-51. PubMed ID: 19261819
    [Abstract] [Full Text] [Related]

  • 5. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007004. PubMed ID: 19588415
    [Abstract] [Full Text] [Related]

  • 6. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
    Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, van den Meiracker AH, Saklayen MG, Oveisi S, Jardine AG, Delles C, Preiss DJ, Mark PB.
    BMC Nephrol; 2016 Sep 08; 17(1):127. PubMed ID: 27609359
    [Abstract] [Full Text] [Related]

  • 7. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 08; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 8. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL, Townsend RR.
    J Am Soc Nephrol; 2009 Aug 08; 20(8):1666-8. PubMed ID: 18776118
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
    MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.
    Am J Kidney Dis; 2006 Jul 08; 48(1):8-20. PubMed ID: 16797382
    [Abstract] [Full Text] [Related]

  • 10. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R, Rios P, Baldovinos G, Chichet MA, Perg N, Sola L, Saona G, De Souza N, Lamadrid V, Gadola L.
    Nephron; 2019 Jul 08; 143(2):100-107. PubMed ID: 31203280
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
    Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL.
    Am J Hypertens; 2013 Mar 08; 26(3):424-41. PubMed ID: 23382494
    [Abstract] [Full Text] [Related]

  • 12. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov 08; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 13. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H.
    Am J Kidney Dis; 2016 May 08; 67(5):728-41. PubMed ID: 26597926
    [Abstract] [Full Text] [Related]

  • 14. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2005 Jul 08; 46(1):45-51. PubMed ID: 15983956
    [Abstract] [Full Text] [Related]

  • 15. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 08; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 16. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH.
    Kidney Int; 2016 Sep 08; 90(3):696-704. PubMed ID: 27350174
    [Abstract] [Full Text] [Related]

  • 17. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.
    Nefrologia; 2015 Sep 08; 35(6):554-61. PubMed ID: 26519114
    [Abstract] [Full Text] [Related]

  • 18. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun 08; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 19. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H, Nelges C, Täger T, Schwenger V, Cebola R, Schnorbach J, Goode KM, Kazmi S, Katus HA, Cleland JG, Clark AL, Frankenstein L.
    Am Heart J; 2016 Aug 08; 178():28-36. PubMed ID: 27502849
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S, Bigazzi R, Campese VM.
    Kidney Int; 2006 Dec 08; 70(12):2116-23. PubMed ID: 17035949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.